Allergan plc reported its fourth quarter and full year 2016 continuing operations performance. Total net revenues were $3.9 billion, a 7% increase versus the prior year quarter.

For the full year 2016, Allergan reported total net revenues of $14.57 billion, a 15% increase versus the prior year.

Allergan’s Eye Care franchise experienced strong results versus the prior year. RESTASIS® net revenues were $393.1 million in the fourth quarter of 2016, up 13%, driven by demand and pricing.

The Glaucoma franchise experienced a modest decline, with net revenues in the fourth quarter of 2016 of $102.3 million, up 2% versus prior year quarter offset by LUMIGAN® net revenues declining 9%.

OZURDEX® net revenues in the fourth quarter of 2016 were strong at $22.6 million, up 18% versus prior year quarter driven by continued strong demand from the diabetic macular edema indication.

“2016 was a year of transformation for Allergan. We are now a branded biopharmaceutical leader, focused on delivering sustainable revenue growth, advancing our pipeline, maintaining industry leading margins and allocating capital to maximize shareholder return. In the fourth quarter of 2016, we delivered against these priorities,” says  Brent Saunders, Chairman and CEO of Allergan.

View the complete press release here.